Parkman Healthcare Partners LLC Has $4.35 Million Holdings in Urogen Pharma $URGN

Key Points

• Parkman Healthcare Partners LLC increased its stake in Urogen Pharma by 6.3% in the first quarter, owning a total of 393,153 shares valued at approximately $4.35 million as of the latest reporting period.
• In the most recent quarter, Urogen Pharma reported a loss of ($1.05) per share, missing analysts' expectations and reflecting a negative return on equity of 97,487.15%.
• Analysts have mixed opinions on Urogen Pharma, with ratings ranging from "Strong Buy" to "Hold" and price targets varying from $16.00 to $36.00, indicating differing sentiments on stock valuation.

Parkman Healthcare Partners LLC grew its holdings in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 6.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 393,153 shares of the company's stock after acquiring an additional 23,292 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.85% of Urogen Pharma worth $4,348,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of URGN. Lazard Asset Management LLC bought a new stake in shares of Urogen Pharma during the fourth quarter valued at about $67,000. Janus Henderson Group PLC acquired a new position in Urogen Pharma during the 4th quarter valued at about $149,000. ProShare Advisors LLC bought a new stake in shares of Urogen Pharma during the 4th quarter worth about $137,000. Rhumbline Advisers lifted its stake in shares of Urogen Pharma by 4.3% in the 1st quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock worth $591,000 after acquiring an additional 2,196 shares during the period. Finally, Nuveen LLC bought a new position in shares of Urogen Pharma in the first quarter valued at approximately $1,028,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Stock Up 0.7%

Shares of NASDAQ URGN traded up $0.14 during mid-day trading on Thursday, hitting $19.25. 895,349 shares of the company traded hands, compared to its average volume of 1,528,504. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $21.71. The stock has a market capitalization of $890.51 million, a price-to-earnings ratio of -5.80 and a beta of 1.10. The business has a 50 day moving average of $17.97 and a two-hundred day moving average of $12.72.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to analysts' expectations of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. As a group, research analysts anticipate that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity

In related news, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the transaction, the insider directly owned 148,229 shares of the company's stock, valued at approximately $2,622,171.01. The trade was a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Jason Drew Smith sold 7,522 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the transaction, the general counsel owned 41,492 shares in the company, valued at approximately $794,156.88. This represents a 15.35% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,062 shares of company stock worth $465,115. Company insiders own 4.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on URGN shares. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. Piper Sandler assumed coverage on Urogen Pharma in a research note on Monday, August 18th. They issued an "overweight" rating and a $36.00 price objective on the stock. Guggenheim reaffirmed a "buy" rating and set a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. HC Wainwright dropped their price target on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Urogen Pharma presently has an average rating of "Buy" and a consensus price target of $32.00.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.